As filed with the Securities and Exchange Commission on July 21, 2017

Registration No. 333-151263

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

 

Post-Effective Amendment No. 1 to

FORM S-8

REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933

 

 

 

China Biologic Products Holdings, Inc.

(As successor in interest to China Biologic Products, Inc.)

(Exact name of registrant as specified in its charter)

 

 

 

Cayman Islands   75-2308816
(State or other jurisdiction of incorporation or organization)   (I.R.S. Employer Identification Number)

 

18th Floor, Jialong International Building, 19 Chaoyang
Park Road, Chaoyang District, Beijing
  100125
People’s Republic of China   (Zip Code)
(+86) 10-6598-3111    
(Address of Principal Executive Offices)    

 

 

 

China Biologic Products Holdings, Inc.

2008 Equity Incentive Plan (as amended)

(Full title of the plan)

 

 

 

Cogency Global Inc.
10 E. 40th Street, 10th floor
New York, NY 10016
(+1) 212-947-7200
(Name and address and telephone number of agent for service)

 

 

 

With a copy to:
Howard Zhang
Davis Polk & Wardwell LLP
2201 China World Office 2, 1 Jian Guo Men Wai Avenue, Chaoyang District
Beijing 100004, People’s Republic of China
(+86) 10-8567-5000

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a small reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

 

Large accelerated filer   x   Accelerated filer   ¨
Non-accelerated filer   ¨   Smaller reporting company   ¨
(Do not check if a smaller reporting company)   Emerging growth company   ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ¨

 

 

 

CALCULATION OF REGISTRATION FEE*

 

 

 

Title of securities to be
registered
Amount to be
registered
P roposed maximum
offering price per share
Proposed maximum
aggregate offering price
Amount of
registration fee
           

 

 

 

* No additional securities are to be registered, and the registration fee was previously calculated and paid in connection with the filing of the original Registration Statements (File No. 333-151263). Therefore, no further registration fee is required.

 

 

 

 

 

 

Explanatory Statement

 

This Post-Effective Amendment is being filed pursuant to Rule 414 under the Securities Act of 1933, as amended (the “ Securities Act ”), by China Biologic Products Holdings, Inc., an exempted company incorporated under the laws of the Cayman Islands (the “ Company ”), as successor issuer to China Biologic Products, Inc., a Delaware corporation (“ CBPO DE ”). The Company succeeded to the interests of CBPO DE following a redomicile merger pursuant to an agreement and plan of merger dated as of April 28, 2017 (the “ Merger Agreement ”) between the Company and CBPO DE. Pursuant to the Merger Agreement, CBPO DE merged with and into the Company, with the Company surviving the merger and each issued and outstanding shares of CBPO DE’s common stock being converted into the right to receive one ordinary share of the Company. In addition, the Company assumed CBPO DE’s existing obligations with respect to all outstanding options to purchase shares of CBPO DE’s common stock and all other outstanding equity awards granted to directors, employees and consultants under CBPO DE’s 2008 Equity Incentive Plan to provide for the issuance of an equal number of the Company’s ordinary shares rather than the common stock of CBPO DE upon the exercise of the awards, under the same terms and conditions. This Post-Effective Amendment pertains to the adoption by the Company of the registration statement on Form S-8 (the “ Registration Statement ”) with File No. 333-151263. The Company hereby expressly adopts the Registration Statement as its own registration statement for all purposes of the Securities Act and the Securities Exchange Act of 1934, as amended (the “ Exchange Act ”). This is Post-Effective Amendment No. 1 with respect to the Registration Statement. Registration fees were paid at the time of filing of the original Registration Statement.

 

 

 

 

PART II

 

INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

 

Item 3. Information Incorporated by Reference.

 

The following documents previously filed by CBPO DE or the Company with the Securities and Exchange Commission (the “ Commission ”) pursuant to the Exchange Act are incorporated by reference in this Registration Statement:

 

  (a) CBPO DE’s Annual Report on Form 10-K for the fiscal year ended December 31, 2016 and filed with the Commission on February 23, 2017, as amended by Amendment No. 1 to the Annual Report on Form 10-K for the fiscal year ended December 31, 2016 filed with the Commission on April 28, 2017;

 

  (b) CBPO DE’s Quarterly Reports on Form 10-Q for the quarter ended March 31, 2017 and filed with the Commission on May 3, 2017;

 

  (c) CBPO DE’s Current Reports on Form 8-K filed with the Commission on January 4, 2017, January 6, 2017, February 23, 2017, April 28, 2017, May 3, 2017 and June 30, 2017.

 

  (d) The description of ordinary shares of the Company contained under the heading “Description of Share Capital of CBPO Cayman” in the Company’s registration statement on Form F-4 (File No. 333-217564) filed with the Commission on April 28, 2017, including any amendment or report filed for the purpose of updating such description.

 

All other documents subsequently filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act prior to the filing of a post-effective amendment to this Registration Statement which indicates that all securities offered have been sold or which deregisters all such securities then remaining unsold, shall be deemed to be incorporated by reference in this Registration Statement and to be a part hereof from the date of filing of such documents. Any statement contained herein or in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes such earlier statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

 

Item 4. Description of Securities.

 

Not applicable.

 

Item 5. Interests of Named Experts and Counsel.

 

Not applicable.

 

 

 

 

Item 6. Indemnification of Directors and Officers.

 

Cayman Islands law does not limit the extent to which a company’s articles of association may provide for indemnification of officers and directors, except to the extent any such provision may be held by the Cayman Islands courts to be contrary to public policy, such as to provide indemnification against civil fraud or the consequences of committing a crime.

 

The Company’s articles of association provide that its directors and officers shall be indemnified out of the assets of the Company against any liability, action, proceeding, claim, demand, costs, damages or expenses, including legal expenses, whatsoever which they or any of them may incur as a result of any act or failure to act in carrying out their functions other than such liability (if any) that they may incur by reason of their own actual fraud or wilful default.

 

The Company expects to enter into indemnification agreements with each of its directors, executive officers and other officers and employees (including officers and employees of its subsidiaries) who currently have indemnification agreements with CBPO DE. In addition, the Company expects to have insurance coverage under policies which insure directors and officers against certain liabilities which might be incurred by them in such capacity.

 

Item 7. Exemption from Registration Claimed.

 

Not applicable.

 

Item 8. Exhibits.  

 

Exhibit
Number
  Description
4.1   Amended and Restated Memorandum and Articles of Association of China Biologic Products Holdings, Inc.  (incorporated by reference to Exhibit 3.2 to the Registration Statement on Form F-4 (Reg. No. 333-217564), filed by China Biologic Products Holdings, Inc. on April 28, 2017 and as amended on May 17, 2017.
   
4.2   China Biologic Products Holdings, Inc. 2008 Equity Incentive Plan (as assumed and amended on July 21, 2017).
   
5.1   Opinion of Maples and Calder (Hong Kong) LLP regarding the legality of the registered shares.
   
23.1   Consent of Maples and Calder (Hong Kong) LLP (included in Exhibit 5.1 filed hereto).
   
23.2   Consent of Independent Registered Public Accounting Firm — KPMG Huazhen LLP.
   
24.1   Power of Attorney (included in the signature page to this Registration Statement).

 

Item 9. Undertakings.

 

(a) The undersigned Registrant hereby undertakes:

 

(1) To file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:

 

 

 

 

(i) To include any prospectus required by Section 10(a)(3) of the Securities Act;

 

(ii) To reflect in the prospectus any facts or events arising after the effective date of this Registration Statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in this Registration Statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than a 20 % change in the maximum aggregate offering price set forth in the “Calculation of Registration Fee” table in the effective registration statement; and

 

(iii) To include any material information with respect to the plan of distribution not previously disclosed in this Registration Statement or any material change to such information in this Registration Statement;

 

provided , however , that paragraphs (a)(1)(i) and (a)(1)(ii) do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in periodic reports filed by the Registrant pursuant to Section 13 or Section 15(d) of the Exchange Act that are incorporated by reference in this Registration Statement.

 

(2) That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

 

(3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

 

(b) The undersigned Registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the Registrant’s annual report pursuant to Section 13(a) or Section 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in this Registration Statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

 

(c) Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Act, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Post-Effective Amendment to the Registration Statements to be signed on its behalf by the undersigned, thereunto duly authorized, in Beijing, PRC on July 21, 2017.

 

  China Biologic Products Holdings, Inc.
     
  By: /s/ David (Xiaoying) Gao
    David (Xiaoying) Gao
    Chief Executive Officer
    (Principal Executive Officer)
     
  By: /s/ Ming Yang
    Ming Yang
    Chief Financial Officer
    (Principal Financial Officer and
Principal Accounting Officer)

 

POWER OF ATTORNEY

 

KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints each of David (Xiaoying) Gao and Ming Yang as such person’s true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for such person and in such person’s name, place and stead, in any and all capacities, to sign any amendments to the Registration Statement, including post-effective amendments, and registration statements filed pursuant to Rule 462(b) under the Securities Act, and to file the same, with exhibits thereto and other documents in connection therewith, with the Commission, and does hereby grant unto each said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as such person might or could do in person, hereby ratifying and confirming all that each of said attorney-in-fact and agent, or his substitute therefor, may lawfully do or cause to be done by virtue hereof.

 

Pursuant to the requirements of the Securities Act, this Registration Statement has been signed by the following persons in the capacities and on the date indicated.

 

 

 

 

SIGNATURE   TITLE   DATE
     
/s/ David (Xiaoying) Gao       July 21, 2017
David (Xiaoying) Gao   Chairman of the Board    
     
/s/ Ming Yang       July 21, 2017
Ming Yang   Chief Financial Officer    
     
/s/ Sean Shao       July 21, 2017
Sean Shao   Director    
     
/s/ Zhijun Tong       July 21, 2017
Zhijun Tong   Director    
     
/s/ Yungang Lu       July 21, 2017
Yungang Lu   Director    
     
/s/ Wenfang Liu       July 21, 2017
Wenfang Liu   Director    
     
/s/ Albert (Wai Keung) Yeung       July 21, 2017
Albert (Wai Keung) Yeung   Director    
     
/s/ David Hui Li       July 21, 2017
David Hui Li   Director    
     
/s/ Joseph Chow       July 21, 2017
Joseph Chow   Director    

 

 

 

 

SIGNATURE OF AUTHORIZED REPRESENTATIVE OF THE REGISTRANT

 

Pursuant to the Securities Act, the undersigned, the duly authorized representative in the United States of China Biologic Products Holdings, Inc., has signed this registration statement in Beijing, PRC, on July 21, 2017.

 

  AUTHORIZED U.S. REPRESENTATIVE
   
  /s/ David (Xiaoying) Gao
  Name: David (Xiaoying) Gao
  Title: Chief Executive Officer of China
Biologic Products Holdings, Inc.

 

 

 

 

INDEX TO EXHIBITS

 

Exhibit
Number
  Description
   
4.1   Amended and Restated Memorandum and Articles of Association of China Biologic Products Holdings, Inc.  (incorporated by reference to Exhibit 3.2 to the Registration Statement on Form F-4 (Reg. No. 333-217564), filed by China Biologic Products Holdings, Inc. on April 28, 2017 and as amended on May 17, 2017.
   
4.2   China Biologic Products Holdings, Inc. 2008 Equity Incentive Plan (as assumed and amended on July 21, 2017).
   
5.1   Opinion of Maples and Calder (Hong Kong) LLP regarding the legality of the registered shares.
   
23.1   Consent of Maples and Calder (Hong Kong) LLP (included in Exhibit 5.1 filed hereto).
   
23.2   Consent of Independent Registered Public Accounting Firm — KPMG Huazhen LLP
   
24.1   Power of Attorney (included in the signature page to this Registration Statement).

 

 

 

Exhibit 4.2

 

CHINA BIOLOGIC PRODUCTS HOLDINGS, INC.

 

2008 EQUITY INCENTIVE PLAN
(as assumed and amended on July 21, 2017)

 

1.           Purposes . This Plan permits the Administrator to grant Options, Restricted Shares, Restricted Share Units, Share Appreciation Rights, and Other Share-Based Awards in order to retain, attract and motivate Employees, Directors and Consultants and to provide such persons with equity ownership opportunities and performance-based incentives that are intended to align their interests with those of our shareholders.

 

2.           Shares Subject to the Plan . Subject to adjustment as provided in Section 12, a maximum of five million (5,000,000) Shares will be available for issuance under the Plan. The Shares may be authorized and unissued Shares or Shares now held or subsequently acquired by the Company.

 

If an Award granted under the Plan lapses, is forfeited, terminated or canceled, or expires without being exercised or without the issuance of Shares, the unissued and unpurchased Shares subject to the Award will become available for future grant or sale under the Plan (unless the Plan has terminated).

 

Shares that have actually been issued under the Plan under any Award will not be returned to the Plan and will not become available for grant or sale under the Plan. With respect to SARs, only Shares actually issued pursuant to a SAR will cease to be available under the Plan; all remaining Shares subject to the SARs will remain available for future grant or sale under the Plan (unless the Plan has terminated). Except with respect to issued Shares, Shares withheld by the Company to pay the exercise price of an Award or to satisfy tax withholding obligations with respect to an Award will become available for future grant or sale under the Plan. To the extent an Award under the Plan is paid out in cash rather than Shares, such cash payment will not reduce the number of Shares available for issuance under the Plan.

 

The Company, during the term of this Plan, will at all time reserve and keep available such number of Shares as will be sufficient to satisfy the requirements of the Plan.

 

3.           Administration of the Plan .

 

(a)           Administration . The Board will act as Plan Administrator or will appoint a Committee consistent with Applicable Laws to act as Administrator. If and so long as the Shares are registered under Section 12(b) or 12(g) of the Exchange Act, the Board will consider in selecting the membership of any Committee acting as Administrator the requirements regarding (i) “nonemployee directors” within the meaning of Rule 16b-3 under the Exchange Act; (ii) “independent directors” as described in the listing requirements for any stock exchange on which Shares are listed; and (iii) Section 14(b)(i) of the Plan if the Company pays salaries for which it claims on its U.S. tax returns deductions that are subject to the Code section 162(m) limitation. The Board will determine any Committee member’s term and may remove a Committee member at any time.

 

     

 

 

(b)           Powers of the Administrator . The Administrator will, to the maximum extent permitted by Applicable Laws and the Plan, have full and sole discretionary authority:

 

(i)          to determine Fair Market Value;

 

(ii)         to select the Service Providers to whom Awards may be granted;

 

(iii)           to determine the number of Shares to be covered by each Award;

 

(iv)        to approve forms of agreement for use under the Plan;

 

(v)         to determine the terms and conditions of each Award, including without limitation, the exercise price, amount, the exercise period, vesting conditions, any vesting acceleration, any waiver of forfeiture restrictions, and any other restriction, condition, or limitation regarding any Award or its related Shares;

 

(vi)        to construe and interpret the terms of the Plan and Awards and resolve any disputes regarding Plan and Award provisions;

 

(vii)       to prescribe, amend and rescind rules and regulations relating to the Plan;

 

(viii)        to modify or amend each Award;

 

(ix)         to allow Participants to satisfy withholding tax obligations as permitted by Section 13;

 

(x)         to authorize any person to execute instruments to effectuate an Award;

 

(xi)        to delay issuance of Shares or suspend a Participant’s right to exercise an Award to comply with Applicable Laws; and

 

(xii)       to determine any issues necessary or advisable for administering the Plan.

 

(c)           Effect of Administrator’s Decision . Any act or decision of the Administrator will be binding and conclusive on the Company, all Participants, anyone holding an Award, and any person claiming under or through any Participant.

 

  2  

 

 

4.           Eligibility . ISOs may be granted only to Employees who are subject to U.S. tax. NSOs, Restricted Shares, RSUs, SARs, and Other Share-Based Awards may be granted to Service Providers; provided that NSOs and SARs may not be granted to Service Providers of any Parent if the Service Provider is subject to U.S. tax. Service Providers include prospective employees or consultants to whom Awards are granted in connection with written offers of employment or engagement of services, respectively, with the Company; provided that no Award granted to a prospective employee or consultant may be exercised or purchased prior to the commencement of employment or services with the Company.

 

5.           Share Options .

 

(a)           Grant of Options . The Administrator may grant Options in such amounts as it will determine from time to time. The Administrator may grant NSOs, ISOs, or any combination of the two. ISOs will be granted in accordance with Section 14(a) of the Plan. NSOs and SARs granted to U.S. taxpayers will be granted in accordance with Section 14(c) of the Plan.

 

(b)           Option Award Agreement . Each Option will be evidenced by an Award Agreement that will specify the type of Option granted, the exercise price, the number of Shares to which the Option pertains, vesting conditions, the exercise period, restrictions on transferability, and any other terms and conditions specified by the Administrator (which need not be identical among Participants). If the Award Agreement does not specify that the Option is to be treated as an ISO, the Option will be a NSO.

 

(c)           Exercise Price . The exercise price per share with respect to each Option will be determined by the Administrator provided that the exercise price per share cannot be less than the Fair Market Value of a Share on the Grant Date.

 

(d)           Exercisability . An Option may be exercised at such time as the Option vests. No Option will be exercisable after the expiration of ten (10) years from the Grant Date, provided that if an exercise would violate applicable securities laws, the Option will be exercisable no more than thirty (30) days after the exercise of the Option first would no longer violate applicable securities laws. Subject to the terms of the Plan, Options may be exercised at such times, and in such amount and subject to such restrictions as will be determined by the Administrator, in its discretion.

 

(e)           Vesting Conditions . The Administrator may impose any conditions on the vesting of an Option including, but not limited to the achievement of Company-wide, business unit, and individual goals (including, but not limited to continued employment or service).

 

(f)           Modification of Option Awards . The Administrator may accelerate the exercisability of any Option or a portion of any Option. The Administrator may extend the period for exercise generally provided the exercise period is not extended beyond the earlier of the original term of the Option or ten (10) years from the original Grant Date.

 

(g)           Exercise of Option . An Option is exercised when the Company receives: (1) notice of exercise (in such form as the Administrator will specify from time to time) from the person entitled to exercise the Option, and (2) full payment for the Shares with respect to which the Option is exercised (together with all applicable withholding taxes). An Option may not be exercised for a fraction of a Share. Full payment may consist of any consideration and method of payment authorized by the Administrator and permitted by the Award Agreement and the Plan (together with all applicable withholding taxes). Such consideration may consist entirely of:

 

  3  

 

 

(i)          cash;

 

(ii)         check;

 

(iii)        to the extent not prohibited by Section 402 of the Sarbanes-Oxley Act of 2002, a promissory note;

 

(iv)        other Shares, provided the Shares have a Fair Market Value on the date of exercise of the Option equal to the aggregate exercise price for the Shares being purchased;

 

(v)         to the extent not prohibited by Section 402 of the Sarbanes-Oxley Act of 2002, in accordance with any broker-assisted cashless exercise procedures approved by the Company and as in effect from time to time;

 

(vi)        by requesting the Company to withhold such number of Shares then issuable upon exercise of the Option that have an aggregate Fair Market Value equal to the exercise price for the Option being exercised;

 

(vii)       any combination of the foregoing; or

 

(viii)      such other consideration and method of payment for the issuance of Shares to the extent permitted by Applicable Laws.

 

(h)           Shares Issued Upon Exercise . The Company will issue (or cause to be issued) Shares promptly after the Option is exercised. Shares issued upon exercise of an Option will be issued in the name of the Optionee or, if requested by the Optionee, in the name of the Optionee and his or her spouse. Until the Shares are issued (as evidenced by the appropriate entry on the register of members of the Company), no right to vote or receive dividends or any other rights as a shareholder will exist with respect to the Shares, notwithstanding the exercise of the Option. No adjustment will be made for a dividend or other right for which the record date is prior to the date the Shares are issued, except as provided in Section 12.

 

(i)           Forfeiture of Options . All unexercised Options will be forfeited to the Company in accordance with the terms and conditions set forth in the Award Agreement and again will become available for grant under the Plan.

 

6.           Share Appreciation Rights .

 

(a)           Grant of SARs . The Administrator may grant SARs in such amounts as it will determine from time to time.

 

  4  

 

 

(b)           SAR Award Agreement . Each SAR will be evidenced by an Award Agreement that will specify the exercise price, the number of Shares underlying the SAR grant, vesting conditions, the exercise period, restrictions on transferability, and such other terms and conditions specified by the Administrator (which need not be identical among Participants).

 

(c)           Exercise Price . The exercise price per share with respect to each SAR will be determined by the Administrator provided that the exercise price per share cannot be less than the Fair Market Value of a Share on the Grant Date.

 

(d)           Exercisability . A SAR may be exercised at such time as the SAR vests. No SAR will be exercisable after the expiration of ten (10) years from the Grant Date, provided that if an exercise would violate applicable securities laws, the SAR will be exercisable no more than thirty (30) days after the exercise of the SAR first would no longer violate applicable securities laws. Subject to the terms of the Plan, SARs may be exercised at such times, and in such amount and subject to such restrictions as will be determined by the Administrator, in its discretion.

 

(e)           Vesting Conditions . The Administrator may impose any conditions on the vesting of a SAR including, but not limited to the achievement of Company-wide, business unit, and individual goals (including, but not limited to continued employment or service).

 

(f)           Modification of SAR Awards . The Administrator may accelerate the exercisability of any SAR or a portion of any SAR. The Administrator may extend the period for exercise generally provided the exercise period is not extended beyond the earlier of the original term of the SAR or 10 years from the original Grant Date.

 

(g)           Exercise of SAR . Upon exercise of a vested SAR, a Participant will be entitled to receive payment from the Company in an amount no greater than (1) the difference between the Fair Market Value of a Share on the date of exercise over the exercise price; times (2) the number of Shares with respect to which the SAR is exercised. Payment may consist of cash, Shares of equivalent value, or a combination thereof.

 

(i)          If paid in Shares, the Company will issue (or cause to be issued) Shares promptly after the SAR is exercised. Until the Shares are issued (as evidenced by the appropriate entry on the register of members of the Company), no right to vote or receive dividends or any other rights as a shareholder will exist with respect to the Shares, notwithstanding the exercise of the SAR. No adjustment will be made for a dividend or other right for which the record date is prior to the date the Shares are issued, except as provided in Section 12.

 

(ii)         If paid in cash, the Company will pay the participant promptly after the SAR is exercised but in no event later than the 15th day of the third month following the end of the year in which the SAR is exercised.

 

  5  

 

 

(h)           Forfeiture of SARs . All unexercised SARs will be forfeited to the Company in accordance with the terms and conditions set forth in the Award Agreement and again will become available for grant under the Plan.

 

7.           Restricted Shares and Restricted Share Units .

 

(a)           Grant . The Administrator may grant Restricted Shares or RSUs in such amounts and form as it will determine from time to time.

 

(b)           Award Agreement . Each Award of Restricted Shares or RSUs will be evidenced by an Award Agreement that will specify the number and form, vesting conditions, the Period of Restriction, purchase price (if any), method of payment, restrictions on transferability, repurchase rights, and such other terms and conditions specified by the Administrator (which need not be identical among Participants).

 

(c)           Vesting Conditions . The Administrator may impose vesting conditions on awards of Restricted Shares or RSUs including, but not limited to the achievement of Company-wide, business unit, and individual goals (including, but not limited to continued employment or service). Unless the Administrator determines otherwise, Restricted Shares will be held in escrow by the Company until the restrictions on such Shares have lapsed.

 

(d)           Modification of Restricted Shares or RSUs . The Administrator may accelerate or waive the time at which vesting conditions and other restrictions lapse and provide for a complete or partial exception to an employment or service restriction.

 

(e)           Rights During the Restriction Period . During the Period of Restriction, Service Providers who have been granted Restricted Shares may exercise full voting rights and will be entitled to receive all dividends and other distributions paid with respect to those Shares, unless the Administrator determines otherwise. Any such dividends or distributions paid in Shares will be subject to the same restrictions on transferability and forfeitability as the Restricted Shares with respect to which they were paid. Restricted Shares and RSUs may not be sold, transferred, pledged, assigned, or otherwise alienated or hypothecated until the end of the applicable Period of Restriction.

 

(f)           Removal of Restrictions . All restrictions imposed on Restricted Shares and RSUs will lapse and the Period of Restriction will end upon the satisfaction of the vesting conditions imposed by the Administrator at which time:

 

(i)          vested Restricted Shares, if held in escrow, will be released from escrow as soon as practicable after the last day of the Period of Restriction or at such other time as the Administrator may determine, but in no event later than the 15 th day of the third month following the end of the year in which vesting occurred, or

 

(ii)         vested RSUs will be paid in Shares at the time provided for in the Award Agreement, but in no event later than the 15 th day of the third month following the end of the year in which vesting occurred.

 

  6  

 

 

(g)           Forfeiture . All unvested Restricted Shares and RSUs for which restrictions have not lapsed will be forfeited to the Company on the date set forth in the Award Agreement. Forfeited Restricted Shares will revert to the Company and will not be available for grant under the Plan. Forfeited RSUs will become available for grant under the Plan.

 

8.           Other Share-Based Awards . The Administrator may grant Other Share-Based Awards that are payable in, valued in whole or in part by reference to, or otherwise based on or related to Shares as may be deemed by the Administrator to be consistent with the purposes of the Plan. Other Share-Based Awards may include, without limitation, (a) Shares awarded purely as a bonus and not subject to any restrictions or conditions, (b) grants in lieu of cash compensation, (c) other rights convertible or exchangeable into Shares, and (d) awards valued by reference to the value of Shares or the value of securities of or the performance of specified Subsidiaries. The Administrator will have the authority to determine the time or times at which Other Share-Based Awards will be granted, the number of Shares or Share units and the like to be granted or covered pursuant to an Award, and all other terms and conditions of an Award, including, but not limited to, the vesting period (if any), purchase price (if any), and whether such Awards will be payable or paid in cash, Shares or otherwise. Each Other Share-Based Award will be evidenced by an Award Agreement.

 

9.           Cash Settlement . The Administrator, in its sole discretion, may choose to settle any Award, in whole or in part, granted under the Plan in cash in lieu of Shares. The value of such Award on the date of distribution will be determined in the same manner as the Fair Market Value of Shares on the Grant Date of an Option.

 

10.         Leaves of Absence/Transfer Between Locations . Unless the Administrator provides otherwise or as required by Applicable Laws, an Employee will not cease to be an Employee in the case of (a) any leave of absence approved by the Employer or (b) transfers between locations of the Employer or between the Company, its Parent, or any Subsidiary, but vesting of Awards will be suspended during any unpaid leave of absence.

 

11.         Transferability of Awards . An Award may not be sold, pledged, assigned, hypothecated, transferred, or disposed of in any manner other than by will or by the laws of descent or distribution and Options and SARs may be exercised, during the lifetime of the Participant, only by the Participant or the Participant’s legal representative.

 

12.         Adjustments; Dissolution or Liquidation; Merger or Change in Control .

 

(a)           Adjustments . In the event of a reorganization, recapitalization, share split, share dividend, extraordinary cash dividend, combination of shares, merger, consolidation, rights offering, spin off, split off, split up or other event identified by the Committee, the Committee will equitably adjust (i) the number and kind of shares authorized for issuance under the Plan, (ii) the number and kind of shares subject to outstanding Awards, and (iii) the exercise price of Options and SARs.

 

(b)           Dissolution or Liquidation . In the event of the dissolution or liquidation of the Company, the Administrator will notify each Participant as soon as practicable prior to the effective date of such transaction. To the extent it has not been previously exercised, an Award will terminate immediately prior to the dissolution or liquidation.

 

  7  

 

 

(c)           Change in Control . In the event of a merger or Change in Control, the surviving or successor entity may either assume the Company’s rights and obligations with respect to outstanding Awards or substitute outstanding Awards for substantially equivalent property (including, but not limited to comparable equity interests in the surviving or successor entity) that are subject to vesting requirements and repurchase restrictions no less favorable to the Participant than those in effect prior to the merger or Change in Control.

 

In the event that the successor corporation does not assume or substitute Outstanding Awards, the Participant will fully vest in all Awards, all performance goals and vesting criteria will be deemed to have been achieved at target levels, and all restrictions will lapse. Any Option or SAR that is not assumed or substituted in the event of a Change in Control, will be exercisable for a period of time determined by the Administrator in its sole discretion. The Administrator will provide reasonable notice of such exercise period to the Participant, and the Option or SAR will terminate upon the expiration of such exercise period.

 

For the purposes of this Section 12(c) an Award will be considered assumed if, following the Change in Control, the Award confers a right for each Share or Share equivalent subject to the Award to purchase or receive the consideration (or for an Award payable in cash, the fair market value of the consideration) received for each Share on the date of the transaction. If holders were offered a choice of consideration, the type of consideration chosen by the holders of a majority of the outstanding Shares will be used. If the consideration received in the Change in Control is not solely ordinary shares of the successor corporation or its Parent, the Administrator may, with the consent of the successor corporation pay the Award in the form of ordinary shares of the successor corporation or its Parent equal in fair market value to the per share consideration received by holders of Shares in the Change in Control.

 

Notwithstanding anything in this Section 12(c) to the contrary, an Award that vests, is earned or paid-out upon the satisfaction of one or more performance goals will not be considered assumed if the Company or its successor, without the Participant’s consent, modifies any performance goals except a modification made solely to reflect the successor entity’s post-Change in Control corporate structure (or similar entity level structure if the successor entity is not a corporation).

 

13.         Tax Withholding .

 

(a)           Withholding Requirements . Prior to the delivery of any Shares or cash pursuant to an Award (or exercise thereof), the Company will have the power and the right to deduct or withhold, or require a Participant to remit to the Company, an amount sufficient to satisfy federal, state, local, foreign or other taxes required by Applicable Laws to be withheld with respect to such Award (or exercise thereof).

 

  8  

 

 

(b)           Withholding Arrangements . The Administrator may permit a Participant to satisfy tax withholding obligations, in whole or in part and without limitation by (i) paying cash, (ii) electing to have the Company withhold otherwise deliverable Shares having a Fair Market Value (as of the date that the taxes should be withheld) equal to the withholding amount, or (iii) delivering to the Company already-owned Shares having a Fair Market Value (as of the date that the taxes should be withheld) equal to the withholding amount.

 

14.         Provisions Applicable In the Event the Company or the Service Provider is Subject to U.S. Taxation .

 

(a)           Grant of Incentive Share Options . If the Administrator grants Options to Employees that may be subject to U.S. taxation, the Administrator may grant such Employee an ISO. Section 5 of this Plan and the following terms apply to all grants that are intended to qualify as ISO Awards:

 

(i)           Maximum Amount . Subject to adjustment as provided in Section 12, to the extent consistent with Code section 422, not more than an aggregate of five million (5,000,000) Shares may be issued pursuant to the exercise of ISOs granted under the Plan.

 

(ii)          Eligibility . Only Employees of the Company, a Parent or a Subsidiary will be eligible for the grant of ISOs.

 

(iii)         Continuous Employment . The Optionee must remain in the continuous employment of the Company, any Parent, or any Subsidiary from the ISO Grant Date to the date that is three months prior to exercise. Service will be treated as continuous during a leave of absence approved by the Employer that does not exceed three (3) months. A leave of absence approved by the Employer may exceed three (3) months if reemployment upon expiration of such leave is guaranteed by statute or contract. An Option exercised more than three months after termination of employment will be treated as a NSO.

 

(iv)         Award Agreement .

 

(A)         The Administrator will designate Options granted as ISOs in the Award Agreement.

 

(B)         The Award Agreement will specify the term of the ISO. The term will not exceed ten (10) years from the Grant Date or five (5) years from the Grant Date for Ten Percent Owners.

 

(C)         The Award Agreement will specify an exercise price of not less than the Fair Market Value per Share on the Grant Date or one hundred ten percent (110%) of the Fair Market Value per Share on the Grant Date for Ten Percent Owners.

 

  9  

 

 

(D)         The Award Agreement will specify that an ISO is not transferable except by will, beneficiary designation or the laws of descent and distribution.

 

(v)          Limitation on ISOs . To the extent that the aggregate Fair Market Value of the Shares with respect to which ISOs are exercisable for the first time by the Optionee during any calendar year (under all plans of the Company and any Parent or any Subsidiary) exceeds one hundred thousand dollars ($100,000), Options will not qualify as ISOs and will be treated as NSOs. For purposes of this section, ISOs will be taken into account in the order in which they were granted. The Fair Market Value of the Shares will be determined as of the Grant Date.

 

(vi)         Notice Required Upon Disqualifying Dispositions . The Optionee must notify the Company in writing within thirty (30) days after any disposition of Shares acquired pursuant to the exercise of an ISO within two years from the Grant Date or one year from the exercise date. The Optionee must also provide the Company with all information that the Company reasonably requests in connection with determining the amount and character of Optionee’s income, the Company’s deduction, and the Company’s obligation to withhold taxes or other amounts incurred by reason of a disqualifying disposition.

 

(b)           Performance-Based Compensation . The Administrator may impose the following conditions on any Award under this Plan to any Service Provider that may be subject to U.S. taxation on the Award:

 

(i)           Outside Directors . Awards that the Administrator intends to qualify as “performance-based compensation” must be (A) granted by a committee of the Board comprised solely of two or more “outside directors” within the meaning of Code section 162(m) and (B) administered in a manner that will enable such Awards to qualify as “performance-based compensation” within the meaning of Code section 162(m).

 

(ii)          Maximum Amount . In any calendar year, no eligible Employee may receive (A) with respect to Awards denominated in Shares, Awards covering more than five hundred thousand (500,000) Shares (adjusted in accordance with Section 12), or (B) with respect to Awards denominated in cash, Awards with a Fair Market Value exceeding that of five hundred thousand (500,000) Shares determined as of the Grant Date.

 

(iii)         Performance Criteria . The performance goal applicable to any Award (other than an Option or SAR) that is intended to qualify as performance-based compensation must be established in writing prior to the beginning of the Performance Period or at a later time as permitted by Code section 162(m) and may be based on any one or more of the following performance measures that apply to the individual, a business unit, or the Company as a whole:

 

  10  

 

 

(A)         increased revenue;

 

(B)         net income measures (including but not limited to income after capital costs and income before or after taxes);

 

(C)         share price measures (including but not limited to growth measures and total shareholder return);

 

(D)         market share;

 

(E)         earnings per Share (actual or targeted growth);

 

(F)         earnings before interest, taxes, depreciation, and amortization (“ EBITDA ”);

 

(G)         cash flow measures (including but not limited to net cash flow and net cash flow before financing activities);

 

(H)         return measures (including but not limited to return on equity, return on average assets, return on capital, risk-adjusted return on capital, return on investors’ capital and return on average equity);

 

(I)         operating measures (including operating income, funds from operations, cash from operations, after-tax operating income, sales volumes, production volumes, and production efficiency);

 

(J)         expense measures (including but not limited to overhead cost and general and administrative expense);

 

(K)         margins;

 

(L)         shareholder value;

 

(M)         total shareholder return;

 

(N)         proceeds from dispositions;

 

(O)         production volumes;

 

(P)         total market value; and

 

(Q)         corporate values measures (including but not limited to ethics compliance, environmental, and safety).

 

(iv)        The terms of the performance goal applicable to any Award that is intended to qualify as performance-based compensation must preclude discretion to increase the amount of compensation that would otherwise be due upon attainment of the goal.

 

  11  

 

 

(v)         Following the completion of the Performance Period, the outside directors described in Section 14(b)(i) above must certify in writing whether the applicable performance goals have been achieved for such Performance Period. In determining the amount earned, the Administrator will have the right to reduce (but not increase) the amount payable at a given level of performance to take into account additional factors that the Administrator may deem relevant to the assessment of individual or corporate performance for the Performance Period.

 

(c)           Share Options and SARs Exempt from Code section 409A . Section 5 of this Plan and the following terms apply to all grants of NSOs and SARs to Service Providers that are subject to U.S. taxation.

 

(i)           Eligibility . Only Service Providers of the Company or a Related Entity will be eligible for the grant of NSOs or SARs intended to be exempt from Code section 409A.

 

(ii)          Administration .

 

(A)         The Administrator may not modify or amend the Options or SARs to the extent that the modification or amendment adds a feature allowing for additional deferral within the meaning of Code section 409A, and

 

(B)         any adjustment pursuant to Section 12 will be done in a manner consistent with Code section 409A and Treasury Regulations section 1.409A-1 et seq .

 

(C)         The Company intends that no payments under this Plan will be subject to the tax imposed by Code section 409A. The Administrator will interpret and administer the Plan in a manner that avoids the imposition of any increase in tax under Code section 409A(a)(1)(B), and any ambiguities herein will be interpreted to satisfy the requirements of Code section 409A or any exemption thereto.

 

15.         No Effect on Employment or Service . Neither the Plan nor any Award will confer upon any Participant any right with respect to continuing the Participant’s relationship as a Service Provider with the Company, any Parent or any Subsidiary, nor will either interfere in any way with the Participant’s right or the Company’s or its Parent’s or Subsidiary’s right to terminate such relationship at any time, with or without cause, to the extent permitted by Applicable Laws.

 

16.         Effective Date . The Plan’s effective date is May 9, 2008.

 

17.         Term of Plan . The Plan will terminate on May 9, 2018, unless sooner terminated by the Board pursuant to Section 18.

 

18.         Amendment and Termination of the Plan .

 

  12  

 

 

(a)           Amendment and Termination . The Board may at any time amend, alter, suspend or terminate the Plan.

 

(b)           Shareholder Approval . The Company will obtain shareholder approval of any Plan amendment to the extent necessary and desirable to comply with Applicable Laws.

 

(c)           Effect of Amendment or Termination . No amendment, alteration, suspension or termination of the Plan will impair the rights of any Participant, unless mutually agreed otherwise between the Participant and the Administrator, which agreement must be in writing and signed by the Participant and the Company. Termination of the Plan will not affect the Administrator’s ability to exercise its powers with respect to Awards granted under the Plan prior to the Plan termination date.

 

19.         Conditions Upon Issuance of Shares .

 

(a)           Legal Compliance . The Administrator may delay or suspend the issuance and delivery of Shares, suspend the exercise of Options or SARs, or suspend the Plan as necessary to comply with Applicable Laws. Shares will not be issued pursuant to the exercise of an Award unless the exercise of such Award and the issuance and delivery of such Shares will comply with Applicable Laws and will be further subject to the approval of counsel for the Company with respect to such compliance.

 

(b)           Investment Representations . The Company may require any person exercising or purchasing an Award to represent and warrant that the Shares are being purchased only for investment and without any present intention to sell or distribute such Shares.

 

20.         Inability to Obtain Authority . If the Company is unable to obtain required authority from any regulatory body in order to lawfully issue or sell Shares pursuant to this Plan, all rights with respect to such Shares will be void and the Company will have no liability with respect to the failure to issue or sell such Shares.

 

21.         Repricing Prohibited; Exchange and Buyout of Awards . The repricing of Options or SARs is prohibited without prior shareholder approval. The Administrator may authorize the Company, with prior shareholder approval and the consent of the respective Participants, to issue new Option or SAR Awards in exchange for the surrender and cancellation of any or all outstanding Awards. The Administrator may repurchase Options with payment in cash, Shares or other consideration at any time pursuant to terms that are mutually agreeable to the Company and the Participant..

 

22.         Governing Law . The Plan, any Award Agreement, and documents evidencing Awards or rights relating to Awards will be construed, administered, and governed in all respects under and by the laws of the State of Delaware, without giving effect to its conflicts or choice of law principles.

 

  13  

 

 

23.         Definitions . The following definitions apply to capitalized terms in the Plan:

 

Administrator ” means the Board or Committee that administers the Plan pursuant to Section 3.

 

Applicable Laws ” means the requirements relating to the administration of equity-based awards under Cayman Islands laws, U.S. state corporate laws, U.S. federal and state securities laws, the Code, any stock exchange or quotation system on which the Shares are listed or quoted and the applicable laws of any foreign country or jurisdiction where Awards are, or will be, granted under the Plan.

 

Award ” means an Option, a SAR, a Restricted Share, a RSU, or an Other Share-Based Award granted pursuant to the terms of the Plan.

 

Award Agreement ” means the written agreement governing Plan Awards. The Award Agreement is subject to the terms and conditions of the Plan.

 

Board ” means the Board of Directors of the Company.

 

Change in Control ” means the occurrence of any of the following events:

 

(i)          Any “person” (as such term is used in Sections 13(d) and 14(d) of the Exchange Act) who becomes the “beneficial owner” (as defined in Rule 13d-3 of the Exchange Act), directly or indirectly, of securities of the Company representing fifty percent (50%) or more of the total voting power represented by the Company’s then outstanding voting securities except an acquisition of securities directly from the Company; or

 

(ii)         The consummation of the sale or disposition by the Company of all or substantially all of the Company’s assets;

 

(iii)        A change in the composition of the Board occurring within a two-year period that results in a Board where the majority of the Directors (1) were elected or nominated in connection with an actual or threatened proxy contest involving Director elections, (2) were not Directors as of the effective date of the Plan, or (3) were not elected, or nominated for election, to the Board with the affirmative votes of a majority of the Directors who, at the time of the election or nomination were either Directors as of the effective date of the Plan or Directors elected or nominated as herein described; or a combination of the three; or

 

(iv)        The consummation of a merger or consolidation of the Company with any other entity, unless the voting securities of the Company immediately prior to the merger or consolidation remain outstanding or are converted into voting securities of the surviving entity or parent so that they continue to represent at least fifty percent (50%) of the total voting power represented by the voting securities of the surviving entity (or parent) outstanding immediately after such merger or consolidation.

 

Code ” means the Internal Revenue Code of 1986, as amended. Any reference in the Plan to a section of the Code will be a reference to any successor or amended section of the Code.

 

  14  

 

 

Committee ” means the compensation committee, if any, or such similar or successor Committee appointed by the Board. If the Board has not appointed a Committee, the Board will function in the place of the Committee.

 

Company ” means China Biologic Products Holdings, Inc., an exempted company incorporated under the laws of the Cayman Islands, or its successor.

 

Consultant ” means any person, including an advisor, if: (1) the consultant or adviser is a natural person; (2) the consultant or adviser renders bona fide services to the Company or any Subsidiary; and (3) the services rendered by the consultant or adviser are not in connection with the offer or sale of securities in a capital-raising transaction and do not directly or indirectly promote or maintain a market for the Company’s securities.

 

Director ” means a member of the Board.

 

Disability ” generally means total and permanent disability as determined by the Administrator in its discretion in accordance with uniform and non-discriminatory standards adopted by the Administrator from time to time, but “Disability,” for purposes of an ISO, means total and permanent disability as defined in Code section 22(e)(3).

 

Employee ” means any person, including Officers and Directors, who is a common law employee of the Company, a Parent, or a Subsidiary. For Options or SARs granted to U.S. taxpayers, Employee means any person, including Officers and Directors, who is a common law employee of the Company or any Related Entity. Neither service as a Director nor payment of a director’s fee by the Company will be sufficient to constitute “ employment ” by the Company.

 

Employer ” means the entity that employs the Employee.

 

Exchange Act ” means the Securities Exchange Act of 1934, as amended.

 

Fair Market Value ” means, as of any date, the value of Shares determined as follows:

 

(i)          If the Shares are listed on any established stock exchange or a national market system, including without limitation any division or subdivision of the NASDAQ Stock Market, its Fair Market Value will be the closing sales price for such Share (or the closing bid, if no sales were reported) as quoted on such exchange or system on the day of determination, as reported in The Wall Street Journal or such other source as the Administrator deems reliable; or

 

(ii)         If the Shares are regularly quoted by a recognized securities dealer but selling prices are not reported, including without limitation quotation through the Over-The-Counter Bulletin Board quotation service administered by the Financial Industry Regulatory Authority, the Fair Market Value of a Share will be the mean between the high bid and low asked prices for the Shares on the day of determination, as reported in The Wall Street Journal or such other source as the Administrator deems reliable; or

 

  15  

 

 

(iii)        In the absence of an established market for the Shares, the Fair Market Value will be determined in good faith by the Administrator, and to the extent Section 14 applies (a) with respect to ISOs, the Fair Market Value will be determined in a manner consistent with Code section 422 or (b) with respect to NSOs or SARs, the Fair Market Value will be determined in a manner consistent with Code section 409A.

 

Fiscal Year ” means the fiscal year of the Company.

 

Grant Date ” means the date on which the Administrator grants an Award, or such other later date as is determined by the Administrator, provided that the Administrator cannot grant an Award prior to the date the material terms of the Award are established. The Administrator may not grant an Award with a Grant Date that is effective prior to the date the Administrator takes action to approve such Award.

 

Incentive Share Option ” or “ ISO ” means an Option intended to qualify as an incentive share option within the meaning of Code section 422 and its regulations.

 

Nonstatutory Share Option ” or “ NSO ” means an Option that by is not intended to qualify as an ISO.

 

Officer ” means a person who is an officer of the Company within the meaning of Section 16 of the Exchange Act and its rules and regulations.

 

Option ” means a share option granted pursuant to the Plan.

 

Optionee ” means the holder of an Option granted pursuant to the Plan.

 

Other Share-Based Awards ” will mean awards of Shares or other rights in accordance with Section 8.

 

Parent ” means a “ parent corporation ” as defined in Code section 424(e).

 

Participant ” means the holder of an Award granted pursuant to the Plan.

 

Performance Period ” means one or more time periods, which may be of varying and overlapping durations, over which the attainment of the performance goals or other vesting conditions will be measured for the purpose of determining a Participant’s right to payment.

 

Period of Restriction ” means the period during which Restricted Share and RSUs are subject to forfeiture or restrictions on transfer pursuant to Section 7.

 

Plan ” means this 2008 Equity Incentive Plan.

 

Related Entity ” means the corporation or other entity, other than the Company, to which the Service Provider provides services on the Grant Date, and any corporation or other entity, other than the Company, in an unbroken chain of corporations or other entities beginning with the Company in which each corporation or other entity has a controlling interest in another corporation or other entity in the chain, and ending with the corporation or other entity that has a controlling interest in the corporation or other entity to which the Service Provider provides services on the Grant Date. For a corporation, a controlling interest means ownership of stock possessing at least fifty (50%) percent of total combined voting power of all classes of stock, or at least fifty (50%) percent of the total value of all classes of stock. For a partnership or limited liability company, a controlling interest means ownership of at least fifty (50%) percent of the profits interest or capital interest of the entity. In determining ownership, the rules of Treasury Regulation sections 1.414(c)-3 and 1.414(c)-4 apply.

 

  16  

 

 

Restricted Share ” means Shares awarded to a Participant that are subject to forfeiture and restrictions on transferability in accordance with Section 7.

 

Restricted Share Unit ” or “ RSU ” means the right to receive one Share at the end of a specified period of time that is subject to forfeiture in accordance with Section 7 of the Plan.

 

Rule 16b-3 ” means Rule 16b-3 of the Exchange Act or any successor to Rule 16b-3.

 

Section 16(b) ” means Section 16(b) of the Exchange Act.

 

Service Provider ” means an Employee, Director or Consultant.

 

Share ” means ordinary shares of a par value of US$0.0001 each in the share capital of the Company, as adjusted in accordance with Section 12.

 

Share Appreciation Right ” or “ SAR ” means the right to receive payment from the Company in an amount no greater than the excess of the Fair Market Value of a Share at the date the SAR is exercised over a specified price fixed by the Administrator in the Award Agreement that is not less than the Fair Market Value of a Share on the Grant Date.

 

Subsidiary ” means a “ subsidiary corporation ” as defined in Code section 424(f).

 

Ten Percent Owner ” means any Service Provider who is, on the Grant Date of an ISO, the owner of more than 10% of the total combined voting power of all classes of shares of the Company, any Parent, or any Subsidiary (determined with application of ownership attribution rules of Code section 424(d)).

 

Adopted by the Board of Directors on May 9, 2008

 

  17  

 

Exhibit 5.1

 

Our ref KKZ/725866-000001/11362913v1
Direct tel +852 3690 7432
Email karen.zhangpallaras@maplesandcalder.com

 

China Biologic Products Holdings, Inc.

18th Floor, Jialong International Building

19 Chaoyang Park Road

Chaoyang District, Beijing 100125

People’s Republic of China

 

21 July 2017

 

Dear Sirs

 

China Biologic Products Holdings, Inc. (the "Company")

 

We have acted as Cayman Islands legal counsel to the Company in connection with a registration statement on Form S-8 to be filed with the Securities and Exchange Commission (the " Commission ") on or about 21 July 2017 (the " Registration Statement ", which term does not include any other document or agreement whether or not specifically referred to therein or attached as an exhibit or schedule thereto) relating to (1) the assumption by the Company, under an Agreement and Plan of Merger dated 28 April 2017 pursuant to which China Biologic Products, Inc., a Delaware corporation and the sole shareholder of the Company (the " Merging Company "), merges with and into the Company, with the Company surviving the merger (the " Merger "), of the Merging Company's existing obligations with respect to all outstanding options to purchase shares of the Merging Company's common stock and all other outstanding equity awards granted to directors, employees and consultants under the Merging Company's 2008 Equity Incentive Plan (as amended on 21 July 2017) (the " Plan ") to provide for the issuance of up to 5,000,000 ordinary shares of a par value of US$0.0001 each in the share capital of the Company (the " Shares ") rather than the common stock of the Merging Company upon the exercise of the awards under the same terms and conditions; and (2) adoption by the Company of the registration statement File No. 333-151263 on Form S-8.

 

For the purposes of giving this opinion, we have examined copies of the Registration Statement and the Plan. We have also reviewed copies of the amended and restated memorandum and articles of association of the Company as adopted by a special resolution passed on 21 July 2017 and effective conditional and immediately upon the completion of the Merger (the " Memorandum and Articles "), and the resolutions of the directors of the Company passed on 21 July, 2017 (the " Resolutions ").

 

Based upon, and subject to, the assumptions and qualifications set out below, and having regard to such legal considerations as we deem relevant, we are of the opinion that:

 

1. The Shares to be issued by the Company have been duly and validly authorised.

 

2. When issued, sold and paid for in accordance with the terms of the Plan and in accordance with the Resolutions, and appropriate entries are made in the register of members (shareholders) of the Company, the Shares will be validly issued, fully paid and non-assessable.

 

     

 

 

In this opinion letter, the phrase "non-assessable" means, with respect to the issuance of Shares, that a shareholder shall not, in respect of the relevant Shares, have any obligation to make further contributions to the Company's assets (except in exceptional circumstances, such as involving fraud, the establishment of an agency relationship or an illegal or improper purpose or other circumstances in which a court may be prepared to pierce or lift the corporate veil).

 

These opinions are subject to the qualification that under the Companies Law (2016 Revision) of the Cayman Islands, the register of members of a Cayman Islands company is by statute regarded as prima facie evidence of any matters which the Companies Law (2016 Revision) directs or authorises to be inserted therein. A third party interest in the shares in question would not appear. An entry in the register of members may yield to a court order for rectification (for example, in the event of fraud or manifest error).

 

These opinions are given only as to, and based on, circumstances and matters of fact existing and known to us on the date of this opinion letter. These opinions only relate to the laws of the Cayman Islands which are in force on the date of this opinion letter. We express no opinion as to the meaning, validity or effect of any references to foreign (i.e. non-Cayman Islands) statutes, rules, regulations, codes, judicial authority or any other promulgations.

 

We have also relied upon the assumptions, which we have not independently verified, that (a) all signatures, initials and seals are genuine, (b) copies of documents, conformed copies or drafts of documents provided to us are true and complete copies of, or in the final forms of, the originals, (c) where a document has been provided to us in draft or undated form, it will be duly executed, dated and unconditionally delivered in the same form as the last version provided to us, (d) the Memorandum and Articles remain in full force and effect and are unamended, (e) the Resolutions were duly passed in the manner prescribed in the Memorandum and Articles and have not been amended, varied or revoked in any respect, (f) there is nothing under any law (other than the laws of the Cayman Islands) which would or might affect the opinions set out below, and (g) upon the issue of any Shares, the Company will receive consideration which shall be equal to at least the par value of such Shares.

 

This opinion letter is to and for the benefit solely of the addressee and may not be relied upon by any other person for any purpose.

 

We consent to the use of this opinion as an exhibit to the Registration Statement and further consent to all references to us in the Registration Statement and any amendments thereto. In giving such consent, we do not consider that we are “experts” within the meaning of such term as used in the Securities Act, or the rules and regulations of the Commission issued thereunder, with respect to any part of the Registration Statement, including this opinion as an exhibit or otherwise.

 

Yours faithfully  
   
/s/ Maples and Calder (Hong Kong) LLP  
   
Maples and Calder (Hong Kong) LLP  

 

      2

 

 

Exhibit 23.2

 

Consent of Independent Registered Public Accounting Firm

 

The Board of Directors

China Biologic Products Holdings, Inc.:

 

We consent to the use of our reports dated February 23, 2017, with respect to the consolidated balance sheets of China Biologic Products, Inc. and subsidiaries as of December 31, 2016 and 2015, and the related consolidated statements of comprehensive income, changes in equity and cash flows for each of the years in the three-year period ended December 31, 2016, and the effectiveness of internal control over financial reporting as of December 31, 2016, incorporated herein by reference.

 

/s/ KPMG Huazhen LLP

 

Beijing, China

 

July 21, 2017